Trial reportMolecular biology reports2025
The effects of nanocurcumin on immune-related factors in the ankylosing spondylitis patients: a double-blind, randomized, placebo-controlled clinical trial.
Trial report in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- OptiSyn: an interpretable, multi-omics-driven graph convolutional network framework for synergy-oriented drug combination design in disease treatment.Chinese medicine · 2026Article
- Restoring adenosine balance in axial spondyloarthritis: a stage-specific framework for immune and structural modulation.Frontiers in immunology · 2026Review
- How Traditional Chinese Medicine Can Play a Role In Nanomedicine? A Comprehensive Review of the Literature.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundA rheumatic condition characterized by inflammation and increased bone mass at the primary sites of inflammation is called ankylosing spondylitis (AS). The pathophysiology of AS has been linked to Th17 and Regulatory T (Treg) cells, as well as the immunological and miRNA variables that are associated with them. This study looked at how immunological and miRNA variables in AS patients' peripheral blood (PB) were affected by nanocurcumin.
methodsFor four months, 30 patients with AS were part of the test group, who got nanocurcumin daily, and 30 patients in the control group, who received a placebo. Using flow cytometry, the frequency of Th17 and Treg was determined. Real-time polymerase chain reaction was used to measure the expression levels of HIF1A, various related microRNAs (miRNAs; miR-18a, miR-206, and miR-30a), and CD39 with CD73 in Patients PBMCs. An enzyme-linked immunosorbent assay was also used to measure the amounts of factors and cytokines secreted in serum.
resultsFollowing treatment with nanocurcumin, patients with AS experienced a large rise in Treg cells and a decrease in Th17 cells. The RT-PCR results showed that while miR-18a was dramatically upregulated after nanocurcumin treatment, the expression of miR-206 and miR-30a was significantly downregulated. Additionally, compared to the control group, the nanocurcumin-treated group had lower levels of HIF-1alpha production and higher levels of IGF-1, TGF-β, CD39, and CD73.
conclusionAccording to the findings, Th17 and Treg cell dysregulation, along with other immunological factors and miRNAs in PB, affects the progression of AS. Nanocurcumin therapy has the potential to control these variables, as well as Th17 and Treg cells, and may, therefore, help treat AS and other autoimmune disorders.
Indexed as
Identifiers
40106064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.